Teva and natco announce launch of additional strengths for the generic version of revlimid® (lenalidomide capsules), in the u.s.

Parsippany, n.j. & tel aviv, israel & hyderabad, india--(business wire)--teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), and natco pharma limited (nse: natcopharm; bse: 524816), announced today the launch of additional strengths for the generic version of revlimid®1 (lenalidomide capsules), in 2.5 mg, and 20 mg strengths, in the united states. the companies have launched four other strengths of the product in march 2022 in the us market.
TEVA Ratings Summary
TEVA Quant Ranking